Shah, T T http://orcid.org/0000-0003-1642-1208
Peters, M
Kanthabalan, A
McCartan, N
Fatola, Y
van der Voort van Zyp, J
van Vulpen, M
Freeman, A
Moore, C M
Arya, M
Emberton, M
Ahmed, H U
Article History
Received: 26 January 2016
Revised: 14 March 2016
Accepted: 20 March 2016
First Online: 19 July 2016
Competing interests
: HU Ahmed acknowledges funding from the Medical Research Council (UK), the Pelican Cancer Foundation Charity, Prostate Cancer UK, St Peters Trust Charity, Prostate Cancer Research Centre the Wellcome Trust, National Institute of Health Research-Health Technology Assessment Programme and the US National Institute of Health-National Cancer Institute. HU Ahmed also receives funding from USHIFU, Trod Medical and Sophiris Biocorp for clinical trials. M Emberton has been awarded National Institute of Health Research (NIHR) Senior Investigator status. He receives research support from the UCLH/UCL NIHR Biomedical Research Centre. M Emberton receives funding from USHIFU, Trod Medical and Sophiris Biocorp for clinical trials and is a consultant for Steba Biotech and USHIFU. He also receives funding from the Medical Research Council (UK), the Pelican Cancer Foundation Charity, Prostate Cancer UK, St Peters Trust Charity, Prostate Cancer Research Centre the Wellcome Trust, National Institute of Health Research-Health Technology Assessment Programme and the US National Institute of Health-National Cancer Institute. TT Shah would like to acknowledge funding from the St Peters Trust for clinical research and has received funding for conference attendance from Astellis, Ferring and Galil Medical. The remaining authors declare no conflicts of interest.